Is it Time to Dump Assertio Holdings Inc (ASRT) Stock After it Has Risen 7.69% in a Week?

The market has been high on Assertio Holdings Inc (ASRT) stock recently. ASRT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Assertio Holdings Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ASRT!

See Full ASRT Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ASRT Stock Today?

Assertio Holdings Inc (ASRT) stock is trading at $3.08 as of 2:24 PM on Friday, May 20, a loss of -$0.05, or -1.6% from the previous closing price of $3.13. The stock has traded between $2.98 and $3.22 so far today. Volume today is 862,144 compared to average volume of 1,017,697. To screen for more stocks like Assertio Holdings Inc click here.

More About Assertio Holdings Inc

Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults 18 years of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain. Click Here to get the full Stock Report for Assertio Holdings Inc stock.